Equity Profile

ELAN

Elanco Animal Health Incorporated

Health CarePharmaceuticals$12.6B

May6Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:27 AM EDT

Elanco Animal Health Beats on EPS, Stock Up 13.88%

Metric	Actual	Expected	Surprise
EPS	$0.40	$0.34	+16.28%
Revenue	—	$1.3B	—

management commentary, guidance changes, and full analysis available with Pro.

Elanco Animal Health Beats on EPS, Stock Up 13.88%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.40	$0.34	+16.28%
Revenue	—	$1.3B	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Elanco Animal Health reported better-than-expected earnings per share, which likely contributed to a strong stock reaction, with shares rising nearly 14%. However, there was no revenue figure provided, leaving some uncertainty about overall performance. Investors may view the EPS beat positively, but the lack of revenue details could lead to caution moving forward.

Company Snapshot

Elanco Animal Health Incorporated focuses on providing products for animal health, including pharmaceuticals and vaccines for livestock and pets. As a key player in the health care sector, the company is significant for its role in ensuring animal well-being and food safety.

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

$0.34

Revenue

Total revenue reflects the overall sales performance and market demand for Elanco's products, which is essential for assessing growth.

$1.3B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+20.15%

Avg Stock Reaction

+9.36%

Last Quarter Recap

In the previous quarter, Elanco reported an EPS of $0.13, exceeding expectations by 16%. The stock reacted positively, gaining 6.59% the following day.

Management Promises & Guidance

Focus on expanding product offerings in the pet health segment.
Commitment to improving operational efficiency.
Plans to enhance research and development for new animal health solutions.

Expectations

Wall Street Expectations

Analysts expect Elanco to report solid earnings this quarter, with a consensus EPS of $0.34 and revenue of $1.3 billion. Investors will be closely watching for any signs of growth in key product areas.

Bull Case

If Elanco beats EPS expectations and shows strong revenue growth, it could signal a recovery in demand and operational improvements, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it may raise concerns about its market position and growth prospects, resulting in a negative stock reaction.

Key Metrics to Watch

EPS

$0.34

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

Revenue

$1.3B

Total revenue reflects the overall sales performance and market demand for Elanco's products, which is essential for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Elanco's EPS exceed the consensus estimate of $0.34?

A beat on EPS could indicate stronger-than-expected profitability and operational efficiency, which would likely boost investor confidence.

What revenue growth can Elanco report compared to the expected $1.3 billion?

Revenue performance is crucial for assessing market demand and growth potential, and any significant deviation could impact stock sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Elanco's ability to leverage its recent product innovations, which could drive stronger revenue growth than anticipated.

Supporting Evidence

Elanco has a history of exceeding EPS expectations, with an 88% beat rate over the last eight quarters.

The options market indicates a significant expected move, suggesting traders anticipate volatility that could favor a positive outcome.

Key Risk

If Elanco reports revenue growth significantly above $1.3 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Elanco can maintain its growth trajectory amid competitive pressures and operational challenges.

Bull Confirmed If

An EPS of $0.36 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.32 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.6%

Historical Avg

±11.3%

In line with history

The options market is pricing in a significant move of about 10.6%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.4% while ELAN has averaged ±11.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.8%

30d HV

38.4%

Calls (82K)P/C Ratio: 0.24Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 3 of 30 (10%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Elanco beats expectations, history suggests a potential stock increase of around 12.8%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss on earnings could lead to a decline of approximately 3.7%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth in the pet health segment.
2Updates on new product launches and their market reception.
3Any commentary on operational efficiency improvements.
4Insights into competitive pressures in the animal health market.
5Management's outlook on future demand trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

$0.34

Revenue

Total revenue reflects the overall sales performance and market demand for Elanco's products, which is essential for assessing growth.

$1.3B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+20.15%

Avg Stock Reaction

+9.36%

Last Quarter Recap

In the previous quarter, Elanco reported an EPS of $0.13, exceeding expectations by 16%. The stock reacted positively, gaining 6.59% the following day.

Management Promises & Guidance

Focus on expanding product offerings in the pet health segment.
Commitment to improving operational efficiency.
Plans to enhance research and development for new animal health solutions.

Expectations

Wall Street Expectations

Bull Case

If Elanco beats EPS expectations and shows strong revenue growth, it could signal a recovery in demand and operational improvements, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it may raise concerns about its market position and growth prospects, resulting in a negative stock reaction.

Key Metrics to Watch

EPS

$0.34

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

Revenue

$1.3B

Total revenue reflects the overall sales performance and market demand for Elanco's products, which is essential for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Elanco's EPS exceed the consensus estimate of $0.34?

A beat on EPS could indicate stronger-than-expected profitability and operational efficiency, which would likely boost investor confidence.

What revenue growth can Elanco report compared to the expected $1.3 billion?

Revenue performance is crucial for assessing market demand and growth potential, and any significant deviation could impact stock sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Elanco's ability to leverage its recent product innovations, which could drive stronger revenue growth than anticipated.

Supporting Evidence

Elanco has a history of exceeding EPS expectations, with an 88% beat rate over the last eight quarters.

The options market indicates a significant expected move, suggesting traders anticipate volatility that could favor a positive outcome.

Key Risk

If Elanco reports revenue growth significantly above $1.3 billion, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Elanco can maintain its growth trajectory amid competitive pressures and operational challenges.

Bull Confirmed If

An EPS of $0.36 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.32 would confirm the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±10.6%

Historical Avg

±11.3%

In line with history

The options market is pricing in a significant move of about 10.6%, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±11.4% while ELAN has averaged ±11.3% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.8%

30d HV

38.4%

Calls (82K)P/C Ratio: 0.24Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options pricing cheap in Health Care

n=30

Fade rate: 3 of 30 (10%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.1%, with a raw directional average of +1.7% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Elanco beats expectations, history suggests a potential stock increase of around 12.8%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.

Miss

A miss on earnings could lead to a decline of approximately 3.7%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue growth in the pet health segment.
2Updates on new product launches and their market reception.
3Any commentary on operational efficiency improvements.
4Insights into competitive pressures in the animal health market.
5Management's outlook on future demand trends.